Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp. (LSAQ)

Go back to Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp. (LSAQ)

Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future

May 7, 2021 7:55 AM EDT

Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research $80 million via LifeSci Acquisition II Corp., a special purpose acquisition company with no public warrants $200 million via fully committed and upsized PIPE from leading institutional and strategic investors including Redmile Group; funds and accounts managed by BlackRock; Casdin Capital; dRx Capital (Novartis Pharma AG); LifeSci Venture Partners; Lux... More